European Collaboration: Towards Drug Developement and Rational Drug Therapy
“European Collaboration: Towards Drug Development and Rational Drug Therapy “ is the title of the 6th Congress of the European Association for Clinical Pharmacology and Therapeutics ( EACPT )being held in Istanbul,Turkey from June 24th -28th 2003. Istanbu
- PDF / 2,595,606 Bytes
- 180 Pages / 547.087 x 765.354 pts Page_size
- 102 Downloads / 203 Views
Springer-Verlag Berlin Heidelberg GmbH
F. C. Tulunay
M. Orme
(Eds.)
European Collaboration: Towards Drug Development and Rational Drug Therapy Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics Istanbul, June 24 – 28, 2003
With 3 Figures and 22 Tables
123
PROFESSOR CANKAT TULUNAY
Clinical Pharmacology Society Department of Pharmacology and Clinical Pharmacology Ankara University Medical School Merkez Bina SIHHIYE 6100 Ankara TURKEY PROFESSOR MICHAEL ORME
EACPT Dept. of Pharmacology and Therapeutics The University of Liverpool Ashton Street, PO Box 147 Liverpool GREAT BRITAIN
Cataloging-in-Publication data applied ior A catalog record for this book is available irom the Library of Congress. Bibliopgraphic information published by Die Deutsche Bibliothek Die Deutsche Bibliothek lists this publication in the Deutesche Nationalbibliografie; detailed bibliographic data is available in the Internet at http://dnh.ddb.de
ISBN 978-3-540-14010-8 DOI 10.1007/978-3-642-55454-4
ISBN 978-3-642-55454-4 (eBook)
This work is subject to copyright. All rights are reserved, whether the whole or part oi the material is concerned, specitically the rights oi translation , reprinting, reuse oi illustrations, recitation, broadcasting, reproduction on microtilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9,1965, in its current version, and permission ior use must always be obtained irom Springer-Verlag. Violations are liable ior prosecution under the German Copyright Law.
http://www.springer.de Springer· Verlag Berlin Heidelberg 2003 Originally published by Springer-Verlag Berlin Heidelberg New York in 2003
(3.5-7 We conclude from these two types of study that in the typical hypertensive patient a large number of genes are each making a small contribution, that will be hard to detect. By contrast, in patients who are atypical for their age group – particular young lowrenin patients with Na+ dependent hypertension – a number of rare monogenic syndromes are recognised which are profoundly sensitive to particular diuretics.8,9 Within essential hypertension, we 8
now recognise resistant hypertension as a clue to the presence of spironolactone sensitive hypertension,9,10 and predict that in this population and their offspring we will find genetic variants increasing secretion or response to aldosterone.9 1. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-2013. 2. Deary A, Schumann A, Murfet H, Haydock S, Foo R, Brown M. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. Journal of Hypertension 2002;20:771-777. 3. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003;17:81-6. 4. Laragh JH, Letcher RL, Pickering TG. Ren
Data Loading...
